We are live on ! Find out more
AVNS

Avanos Medical
AVNS

Delisted

AVNS was delisted on the 24th of July, 2026.

350 hedge funds and large institutions have $1.99B invested in Avanos Medical in 2017 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 95 increasing their positions, 109 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 30

10% more funds holding

Funds holding: 318350 (+32)

4% more capital invested

Capital invested by funds: $1.9B → $1.99B (+$85M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

13% less repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 109

16% less call options, than puts

Call options by funds: $1.78M | Put options by funds: $2.12M

Holders
350
Holders Change
+32
Holders Change %
+10.06%
% of All Funds
7.94%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
64
Increased
95
Reduced
109
Closed
30
Calls
$1.78M
Puts
$2.12M
Net Calls
-$345K
Net Calls Change
-$794K
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$242M -$938K -20,418 -0.4%
BlackRock
2
BlackRock
New York
$228M -$13.5M -293,692 -6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$199M +$3.79M +82,396 +2%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$156M +$4.04M +87,880 +3%
Goldman Sachs
5
Goldman Sachs
New York
$78.9M +$4.2M +91,378 +6%
State Street
6
State Street
Massachusetts
$78.7M +$900K +19,584 +1%
PIM
7
Paradice Investment Management
Colorado
$70M -$2.21M -48,030 -3%
Northern Trust
8
Northern Trust
Illinois
$70M -$1.62M -35,346 -2%
Invesco
9
Invesco
Georgia
$56.4M -$12.9M -279,948 -19%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$42.4M +$1.64M +35,688 +4%
Macquarie Group
11
Macquarie Group
Australia
$39.7M +$20M +435,935 +103%
JP Morgan Chase
12
JP Morgan Chase
New York
$39M +$1.83M +39,846 +5%
Prudential Financial
13
Prudential Financial
New Jersey
$34.6M +$2.93M +63,841 +9%
CRCP
14
Copper Rock Capital Partners
Massachusetts
$31.6M +$1.08M +23,469 +4%
CCM
15
Channing Capital Management
Illinois
$26.4M +$26.3M +571,915 New
Charles Schwab
16
Charles Schwab
California
$26M -$5.89M -128,122 -19%
Wells Fargo
17
Wells Fargo
California
$24.3M +$476K +10,360 +2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$23.3M +$1.39M +30,174 +6%
Norges Bank
19
Norges Bank
Norway
$23.1M +$1.15M +25,075 +5%
TA
20
Teachers Advisors
New York
$18.8M +$2.12M +46,056 +13%
KAM
21
Krensavage Asset Management
New York
$18.2M -$3.84M -83,606 -17%
Lord, Abbett & Co
22
Lord, Abbett & Co
New Jersey
$17.1M -$834K -18,141 -5%
CSC
23
Cove Street Capital
California
$16.6M -$384K -8,365 -2%
PAM
24
Panagora Asset Management
Massachusetts
$16.2M -$7.29M -158,627 -31%
Morgan Stanley
25
Morgan Stanley
New York
$15.8M +$7.52M +163,680 +92%

AVNS Hedge Fund Activity: Q4 2017 in Review

350 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Avanos Medical (AVNS) for Q4 2017, worth a combined $1.99B — up 4.5% from $1.9B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new AVNS positions and 30 closed out — a net gain of 34 holders — while 95 added to existing stakes and 109 trimmed.

The largest buyer was Channing Capital Management, opening a new position worth an estimated $26.3M. The largest seller was BlackRock, cutting an estimated $13.5M.

  • 350 institutional investors held Avanos Medical (AVNS) as of Q4 2017, up from 318 in Q3 2017.
  • Funds reported $1.99B of Avanos Medical stock for Q4 2017, up 4.5% quarter-over-quarter.
  • 64 funds opened new Avanos Medical positions in Q4 2017 and 30 closed out, a net change of +34 holders.
  • The largest Avanos Medical buyer in Q4 2017 was Channing Capital Management, an estimated $26.3M added.
  • The largest Avanos Medical seller in Q4 2017 was BlackRock, an estimated $13.5M sold.

Based on aggregated 13F filings for Q4 2017.